Lv1
50 积分 2025-08-07 加入
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
19天前
已完结
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
22天前
已完结
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial
25天前
已完结
The dedicated “Lp(a) clinic”: A concept whose time has arrived?
3个月前
已完结
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
4个月前
已完结
Real-World Efficacy and Safety of Inclisiran
5个月前
已完结
Proliferation of Human Smooth Muscle Cells Promoted by Lipoprotein(a)
5个月前
已完结
Beyond Discrete Diagnoses: Conceptualizing Obesity-associated Metabolic Disorders as a Unified, Dynamic Continuum
5个月前
已完结
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management
5个月前
已完结
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
5个月前
已完结
皖公网安备34019202002308
